Temferon

Small molecule

GGenenta Science

Temferon is one of 64 small molecule programs targeting Glioblastoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GlioblastomaActive, not recruiting

Multiple MyelomaActive, not recruiting

GlioblastomaPhase 1/Phase 2

Active, not recruiting

Multiple MyelomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

Nolvadex

AstraZeneca

Preclinical

1 6

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 7

Intron a

Systemic Therapy

1 9

Abecma

Bristol-Myers Squibb

Preclinical

4 10

Oblimersen Sodium

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glioblastoma1 trial

A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT

Active, not recruiting·GGenenta Science·Phase 1/2·NCT03866109·27 enrolled

Multiple Myeloma1 trial

A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)

Terminated·GGenenta Science·Phase 1/2·NCT03875495·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Temferon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Temferon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Temferon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genenta Science company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: GGenenta Science

Temferon

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glioblastoma1 trial

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News